Cargando…

Biodrug Delivery Systems: Do mRNA Lipid Nanoparticles Come of Age?

As an appealing alternative to treat and prevent diseases ranging from cancer to COVID-19, mRNA has demonstrated significant clinical effects. Nanotechnology facilitates the successful implementation of the systemic delivery of mRNA for safe human consumption. In this manuscript, we provide an overv...

Descripción completa

Detalles Bibliográficos
Autores principales: Puccetti, Matteo, Schoubben, Aurelie, Giovagnoli, Stefano, Ricci, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917085/
https://www.ncbi.nlm.nih.gov/pubmed/36768539
http://dx.doi.org/10.3390/ijms24032218
_version_ 1784886284739674112
author Puccetti, Matteo
Schoubben, Aurelie
Giovagnoli, Stefano
Ricci, Maurizio
author_facet Puccetti, Matteo
Schoubben, Aurelie
Giovagnoli, Stefano
Ricci, Maurizio
author_sort Puccetti, Matteo
collection PubMed
description As an appealing alternative to treat and prevent diseases ranging from cancer to COVID-19, mRNA has demonstrated significant clinical effects. Nanotechnology facilitates the successful implementation of the systemic delivery of mRNA for safe human consumption. In this manuscript, we provide an overview of current mRNA therapeutic applications and discuss key biological barriers to delivery and recent advances in the development of nonviral systems. The relevant challenges that LNPs face in achieving cost-effective and widespread clinical implementation when delivering mRNA are likewise discussed.
format Online
Article
Text
id pubmed-9917085
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99170852023-02-11 Biodrug Delivery Systems: Do mRNA Lipid Nanoparticles Come of Age? Puccetti, Matteo Schoubben, Aurelie Giovagnoli, Stefano Ricci, Maurizio Int J Mol Sci Review As an appealing alternative to treat and prevent diseases ranging from cancer to COVID-19, mRNA has demonstrated significant clinical effects. Nanotechnology facilitates the successful implementation of the systemic delivery of mRNA for safe human consumption. In this manuscript, we provide an overview of current mRNA therapeutic applications and discuss key biological barriers to delivery and recent advances in the development of nonviral systems. The relevant challenges that LNPs face in achieving cost-effective and widespread clinical implementation when delivering mRNA are likewise discussed. MDPI 2023-01-22 /pmc/articles/PMC9917085/ /pubmed/36768539 http://dx.doi.org/10.3390/ijms24032218 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Puccetti, Matteo
Schoubben, Aurelie
Giovagnoli, Stefano
Ricci, Maurizio
Biodrug Delivery Systems: Do mRNA Lipid Nanoparticles Come of Age?
title Biodrug Delivery Systems: Do mRNA Lipid Nanoparticles Come of Age?
title_full Biodrug Delivery Systems: Do mRNA Lipid Nanoparticles Come of Age?
title_fullStr Biodrug Delivery Systems: Do mRNA Lipid Nanoparticles Come of Age?
title_full_unstemmed Biodrug Delivery Systems: Do mRNA Lipid Nanoparticles Come of Age?
title_short Biodrug Delivery Systems: Do mRNA Lipid Nanoparticles Come of Age?
title_sort biodrug delivery systems: do mrna lipid nanoparticles come of age?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917085/
https://www.ncbi.nlm.nih.gov/pubmed/36768539
http://dx.doi.org/10.3390/ijms24032218
work_keys_str_mv AT puccettimatteo biodrugdeliverysystemsdomrnalipidnanoparticlescomeofage
AT schoubbenaurelie biodrugdeliverysystemsdomrnalipidnanoparticlescomeofage
AT giovagnolistefano biodrugdeliverysystemsdomrnalipidnanoparticlescomeofage
AT riccimaurizio biodrugdeliverysystemsdomrnalipidnanoparticlescomeofage